Abstract |
Methotrexate (MTX) is an active agent in both non-small cell and small cell anaplastic lung cancer. A 26% partial response rate was obtained in 27 previously untreated patients with squamous cell bronchogenic tumors treated with 24-hour infusions of MTX at 400 mg/m2. Responses were seen predominantly in extrathoracic sites. In 38 evaluable patients with small cell carcinomas, 24-hour infusions of MTX at 200 mg/m2 in combination with cyclophosphamide and CCNU produced a 43% complete remission (CR) rate for a median survival of 62 weeks. Fifty-six percent of the CR's were seen in patients with extensive disease.
|
Authors | J F Smyth, H T Ford |
Journal | Cancer treatment reports
(Cancer Treat Rep)
Vol. 65 Suppl 1
Pg. 161-3
( 1981)
ISSN: 0361-5960 [Print] United States |
PMID | 6275986
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Lomustine
- Cyclophosphamide
- Methotrexate
|
Topics |
- Brain Neoplasms
(secondary)
- Carcinoma, Bronchogenic
(drug therapy, mortality, radiotherapy)
- Carcinoma, Small Cell
(drug therapy, mortality, radiotherapy)
- Carcinoma, Squamous Cell
(drug therapy, mortality, radiotherapy)
- Cyclophosphamide
(administration & dosage)
- Drug Administration Schedule
- Drug Therapy, Combination
- Humans
- Infusions, Parenteral
- Lomustine
(administration & dosage)
- Lung Neoplasms
(drug therapy, radiotherapy)
- Methotrexate
(administration & dosage)
- Neoplasm Recurrence, Local
|